


Urethane¹

CAS No. 51-79-6

Reasonably anticipated to be a human carcinogen
First Listed in the *Third Annual Report on Carcinogens* (1983)



Carcinogenicity

Urethane is *reasonably anticipated to be a human carcinogen* based on sufficient evidence of carcinogenicity in experimental animals (IARC 1974, 1982, 1987). When administered in the drinking water, urethane induced lung adenomas, lymphomas (mainly lymphosarcomas), liver angiomas and hemangiomas, papillomas, sebaceous carcinomas of the skin, harderian gland tumors, pulmonary adenomas, squamous cell tumors, mammary carcinomas, and malignant mesenchymal tumors of the fat pad in mice of both sexes; malignant lymphomas, hemangiomas or hemangiosarcomas of the liver, spleen, or uterus, hepatomas, adrenal cortex adenomas, and fibrosarcomas of the mesentery or uterus in female rats; and papillomas, squamous cell carcinomas of the forestomach, malignant lymphomas, mammary tumors, hepatomas, hemangiomas or hemangiosarcomas of the liver, melanotic skin tumors, pulmonary adenomatosis, and adenomatous polyps of the cecum in hamsters of both sexes. When administered by gavage in water followed by topical applications of croton oil, urethane induced an increase in skin papillomas and lung adenomas in mice of both sexes. When administered by gavage in dioctyl ester of sodium sulfosuccinic acid, urethane induced lymphocytic leukemias, stomach papillomas, hepatomas, and pulmonary adenomas in male mice. When applied topically followed by applications of croton oil solution in acetone or when administered in conjunction with dimethylbenz[*a*]anthracene (DMBA), urethane produced skin tumors in mice of both sexes. When administered by inhalation in aerosol sprays (pressure and ultrasonic), urethane induced adenomas and solid squamous tumors in mice of both sexes. When injected subcutaneously postpartum in a gelatin suspension, urethane induced both thymic and malignant lymphomas and pulmonary adenomas in newborn mice of both sexes. When injected subcutaneously, urethane induced leukemia in mice in both sexes. A continuation of these studies also revealed the influence of age as a factor in the susceptibility of the liver to urethane carcinogenesis; hepatomas occurred rapidly among all groups treated neonatally with urethane. When injected subcutaneously, urethane induced melanotic lesions of the iris in newborn rats of both sexes, and adrenal cortical tumors, β -cell tumors of the pancreatic islet cells, forestomach papillomas, lung and intestinal tumors, dermal melanocytomas, and thyroid tumors in newborn hamsters of both sexes. When injected intraperitoneally, urethane induced adenomas in female mice; increased incidences of mammary tumors, Zymbal gland carcinomas, angiomas and sarcomas at various sites, malignant lymphomas, kidney tumors, and epidermal cysts in rats of both sexes; increased incidences of leukemia in male and female newborn mice; malignant lymphomas, lung adenomas, harderian gland tumors, and stromal and epithelial ovarian tumors in rats of both sexes; neoplasms, embryonal kidney tumors, harderian gland adenomas, and Anitschkow cell sarcomas of the heart in both newborn and adult rats of both sexes; and melanotic tumors in male and female newborn hamsters. When injected intraperitoneally in distilled water, urethane induced an increased incidence of hepatomas in partially hepatectomized and nonhepatectomized male mice (IARC 1974). When injected intraperitoneally in sodium chloride followed by a second injection of butylated hydroxytoluene (BHT) in corn oil, urethane induced

increased incidences of alveolar and papillary tumors of the lung in neonatal mice of both sexes (Beer and Malkinson 1985). When injected intraperitoneally or intravenously to female mice before parturition, urethane induced an increased incidence of lung tumors in both sexes of offspring. Subcutaneous injections of urethane to pregnant female mice resulted in enhanced development of hepatomas, ovarian tumors, and pulmonary adenomas in the mothers. When injected intraperitoneally to pregnant female rats, urethane induced hepatomas and sarcomas of the heart in the offspring. When injected subcutaneously, urethane induced pulmonary adenomas in suckling offspring of mice of both sexes. Urethane also enhanced the leukemogenic effect of X-irradiation in mice. X-irradiation combined with administration of urethane led to the induction of mammary carcinomas in mice (IARC 1974).

No adequate human studies of the relationship between exposure to urethane and human cancer have been reported (IARC 1987).

Properties

Urethane may occur as a colorless, odorless columnar crystals or a white, granular powder. It is slightly soluble in olive oil and soluble in water, ether, glycerol, and chloroform. When heated to decomposition, it emits toxic fumes of nitrogen oxides. Urethane is available in the United States as an N.F. grade in the form of a fused solid or crystals that contain 99.43% active ingredient (HSDB 2000, IARC 1974).

Use

The primary use of urethane has been as a chemical intermediate in preparation of amino resins. The process involves a reaction with formaldehyde to give hydroxymethyl derivatives that are used as cross-linking agents in permanent press textile treatments designed to impart wash-and-wear properties to fabrics (IARC 1974). Urethane is also utilized as a solubilizer and co-solvent in the manufacture of pesticides, fumigants, and cosmetics, as an intermediate for pharmaceuticals, and in biochemical research (HSDB 2000). Urethane was formerly used as an active ingredient in drugs prescribed for the treatment of neoplastic diseases, as a sclerosing solution for varicose veins, as a hypnotic, and as a topical bactericide (IARC 1974). In addition, two anticonvulsant drugs, trimethadione and paramethadione, can be contaminated with urethane. The allowable limit has been set at 1 ppm. These anticonvulsant drugs may be used only to treat epilepsy that is refractory to other available drugs (CHIP 1979). It is also used in veterinary medicine as an anesthetic (IARC 1974).

Production

The 1986 Chem Sources USA directory identified one domestic producer (Chem Sources 1986) and Chem Sources (2001) listed 16 current suppliers of urethane. There are no known importers of urethane. The 1979 TSCA Inventory identified five companies producing 6.1 million lb of urethane in 1977 (TSCA 1979). U.S. companies have produced urethane commercially since 1945 (IARC 1974).

Exposure

The primary routes of potential human exposure to urethane are inhalation, ingestion, and dermal contact. When released to soil or water, it is expected to adsorb only weakly and to leach to ground water. In the atmosphere, it will either be washed out by rain or react with photochemically produced hydroxyl radicals (half-life 2.2 days) (HSDB 2000). Formerly, patients treated with pharmaceuticals containing urethane were potentially exposed through injection. Potential human exposure to urethane may occur during its production or use in medical research. Certain epileptic patients may potentially be exposed to urethane as a result of its presence as a contaminant in the

anticonvulsant drugs, trimethadione and paramethadione. The National Occupational Exposure Survey (1981-1983) estimated that 8,005 workers, 5,050 of which were female, were potentially exposed to urethane in the United States (HSDB 2000). Consumers were potentially exposed to urethane residues in textiles treated with the compound. Investigators have found urethane in dimethyl pyrocarbonate-treated beverages and in wine, beer, orange juice, and some soft drinks. Urethane also has been found to occur in foods not treated with dimethyl pyrocarbonate, but made by a fermentation process, including ale, beer, bread, wine, soy sauce, yogurt, and olives (IARC 1974, CHIP 1979, NTP 1996). EPA's Toxic Chemical Release Inventory (TRI) listed three industrial facilities that produced, processed, or otherwise used urethane in 1996 (TRI96 1999). The facilities reported releases of urethane to the environment which were estimated to total 12,538 lb. In 1999, five companies that produced, processed, or otherwise used urethane reported releases to the environment estimated to be 14,340 lb (TRI99 2001).

Regulations

EPA

Clean Air Act

NESHAP: Listed as a Hazardous Air Pollutant (HAP)

Comprehensive Environmental Response, Compensation, and Liability Act

Reportable Quantity (RQ) = 100 lb

Emergency Planning and Community Right-To-Know Act

Toxics Release Inventory: Listed substance subject to reporting requirements

Resource Conservation and Recovery Act

Listed Hazardous Waste: Waste codes in which listing is based wholly or partly on substance - U238

Listed as a Hazardous Constituent of Waste

FDA

Urethane has been withdrawn from the market because it was found to be unsafe or not effective and it cannot be compounded

¹The name urethane is sometimes applied to high-molecular weight polyurethanes used as foams, elastomers, and coatings. Such products are not made from the chemical urethane and do not generate it upon decomposition

REFERENCES

- Beer, D. G. and A. M. Malkinson. 1985. Genetic influence on type 2 or Clara cell origin of pulmonary adenomas in urethane-treated mice. *J Natl Cancer Inst* 75(5): 963-9.
- Chan, P. C. 1996. NTP technical report on toxicity studies of urethane in drinking water and urethane in 5% ethanol administered to F344/N rats and B6C3F1 mice. *Toxic Rep Ser* (52): 1-91, A1-9, B1-9 passim.
- ChemSources. 1986. *Chem Sources, USA*, 27th ed. Ormond Beach, FL: Directories Publishing Company, Inc.
- ChemSources. 2001. *Chemical Sources International, Inc.* <http://www.chemsources.com>.
- CHIP. 1979. *Chemical Hazard Information Profile. Urethane*. Washington, D.C.: U.S. Environmental Protection Agency, Office of Pesticide Programs and Toxic Substances.
- HSDB. 2000. *Hazardous Substances Data Base. National Library of Medicine.* <http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?HSDB>.
- IARC. 1974. *Some Anti-thyroid and Related Substances, Nitrofurans and Industrial Chemicals*. IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans, vol. 7. Lyon, France: International Agency for Research on Cancer. 326 pp.
- IARC. 1982. *Chemicals, Industrial Processes and Industries Associated with Cancer in Humans*. IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans, Supplement 4. Lyon, France: International Agency for Research on Cancer. 292 pp.
- IARC. 1987. *Overall Evaluations of Carcinogenicity. IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans, Supplement 7*. Lyon, France: International Agency for Research on Cancer. 440 pp.
- TRI96. 1998. *Toxic Chemical Release Inventory 1996. Data contained in the Toxic Chemical Release Inventory (TRI)*. National Library of Medicine.
- TRI99. 2001. *Toxic Chemical Release Inventory 1999. Data contained in the Toxic Chemical Release Inventory (TRI)*. National Library of Medicine. <http://www.epa.gov/triexplorer/>.
- TSCA. 1979. *Toxic Substances Control Act, Chemical Substances Inventory*.